This article is a sequence of the Regulatory & Drug Approval Process in the United States, Part-I, which describes the Investigational New Drug (IND) approval process, New Drug Approval (NDA), and Generic drug approval process. In this article, we will discuss the market approval process of biologics, biosimilars, orphan drugs, and various drug approval pathways.  Which is the regulatory authority […]

Read More →

Orphan drug designation for rare disease qualifies the sponsor of the drug for various development incentives of the ODA, including tax credits for qualified clinical testing, so let’s know more about Orphan drug designation Worldwide orphan drug sales are forecast to grow at a CAGR of 12.3% from 2019 to 2024, which is approximately double […]

Read More →

The United States is the region that conducts most clinical trials in the world and is the flag bearer for most clinical research studies requires considering many factors and areas. In the first part of this series of articles for clinical trials in the United States, we have seen the regulatory situation, clinical sites, and […]

Read More →